Fracture recurrence in hip fracture with menopausal hormone therapy versus risedronate: a clinical trial

References

• Malouf-Sierra J, Tarantino U, Garcia-Hernandez PA, et al. Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial. J Bone Miner Res. 2017;32(5):1040–1051.
   PubMed Web of Science ®Google Scholar
• van Staa TP, van Staa TP, van Staa TP, et al. Does a fracture at one site predict later fractures at other sites? Osteoporos Int. 2002;13(8):624–629.
   PubMed Web of Science ®Google Scholar
• Lee YK, Ha YC, Yoon BH, et al. Incidence of second hip fracture and compliant use of bisphosphonate. Osteoporos Int. 2013;24(7):2099–2104.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 2008;90(10):2142–2148.
   PubMed Web of Science ®Google Scholar
• Park YG, Jang S, Ha YC. Incidence, morbidity and mortality in patients older than 50 years with second hip fracture in a jeju cohort study. Hip Pelvis. 2014;26(4):250–255.
   PubMedGoogle Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. N Engl J Med. 2001;344(5):333–340.
   PubMed Web of Science ®Google Scholar
• Osaki M, Tatsuki K, Hashikawa T, et al. Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. Osteoporos Int. 2012;23(2):695–703.
   PubMed Web of Science ®Google Scholar
• McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20.
   PubMed Web of Science ®Google Scholar
• Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011;22(9):2551–2556.
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJ, 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26(3):441–451.
   PubMed Web of Science ®Google Scholar
• Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29(5):1049–1055.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Jama. 2003;290(13):1729–1738.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ. The role of menopausal hormone therapy in the management of osteoporosis. Climacteric. 2015;18(sup2):19–21.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–315.
   PubMed Web of Science ®Google Scholar
• Dupont WD, Plummer WD. Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19(6):589–601.
   PubMedGoogle Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006;21(6):817–828.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288(3):366–368.
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419–427.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428–432.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2011;18(10):1052–1059.
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ (Clinical Research ed). 2010;340:c2519–c2519.
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Christiansen C. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas. 2005;50(2):78–85.
   PubMed Web of Science ®Google Scholar
• Abdi F, Mobedi H, Bayat F, et al. The effects of transdermal estrogen delivery on bone mineral density in postmenopausal women: a meta-analysis. Iran J Pharm Res. 2017;16(1):380–389.
   PubMed Web of Science ®Google Scholar
• L'Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013;16(Suppl 1):44–53.
   PubMed Web of Science ®Google Scholar
• Yoon BK, Lee DY, Park MC, et al. Effects of combination therapy of alendronate and hormonal therapy on bone mineral density in postmenopausal Korean women: multicenter, randomized controlled clinical trial. J Korean Med Sci. 2017;32(6):992–998.
   PubMed Web of Science ®Google Scholar
• Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–374.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. Jama. 2002;287(20):2668–2676.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• Choi DS, Lee DY, Yoon BK. Effects of transdermal estrogen gel in postmenopausal Korean women. J Korean Soc Menopause. 2012;18(2):113–118.
   Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809.
   PubMed Web of Science ®Google Scholar
• Bergman J, Nordstrom A, Hommel A, et al. Bisphosphonates and mortality: confounding in observational studies? Osteoporos Int. 2019;30(10):1973–1982.
   PubMed Web of Science ®Google Scholar
• Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003;14(9):722–727.
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. JAMA. 2017;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Park SY, Kang MI, Park HM, et al. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis. Arch Osteoporos. 2020;15(1):3.
   Web of Science ®Google Scholar
• Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–454.
   PubMed Web of Science ®Google Scholar
• Mohammed K, Abu DA, Benkhadra K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(11):4012–4020.
   PubMed Web of Science ®Google Scholar
• Bezwada P, Shaikh A, Misra D. The effect of transdermal estrogen patch use on cardiovascular outcomes: a systematic review. J Women's Health. 2017;26(12):1319–1325.
   PubMed Web of Science ®Google Scholar